Cancer Research on Prevention and Treatment.2024;51(7):613-616. doi:10.3971/j.issn.1000-8578.2024.23.1381
Cancer Research on Prevention and Treatment
1973 (1, 1) to Present ISSN: 1000-8578
Year of publication
Sort by
DISPLAY OPTIONS
Format:
Per page:
Review of Modern TCM Oncology Academic Thought
Cancer Research on Prevention and Treatment.2023;50(10):929-934. doi:10.3971/j.issn.1000-8578.2023.23.0381
With the establishment of modern traditional Chinese medicine (TCM) as an oncology discipline, it has made great development and progress in the prevention and treatment of tumors. As a result, a number of academic thoughts and viewpoints have emerged. In the tumor field of TCM, the current representative theories include the theory of strengthening the body and treating cancer, the theory of treating from the membrane, the theory of surviving with tumor, the pathogenesis theory of cancer virus, the theory of consolidating the root and clearing the source, and the theory of regulating qi and detoxing. In TCM oncology, a large number of results have been achieved in the research of the thoughts of famous TCM doctors. However, discussions on these thoughts together are relatively few. This article summarizes and studies the above innovative theories from the aspects of academic connotation and clinical application to provide new ideas for further guiding the clinical practice of TCM oncology.
Research Progress on Anal Function-preserving Anastomosis for Low Rectal Cancer
Cancer Research on Prevention and Treatment.2023;50(10):935-940. doi:10.3971/j.issn.1000-8578.2023.23.0617
Rectal cancer is one of the common digestive tract malignant tumors in China. In particular, middle and low rectal cancers are the most common. The treatment goal is to preserve anal function as much as possible through tumor radical resection. Owing to anatomical and biological explorations and the widespread application of new surgical equipment, the possibility of anal function-preserving anastomosis in low rectal cancer has gradually increased. This article reviews the research progress on anastomosis for low rectal cancer surgery and discusses its characteristics and operational difficulties.
Recent Advances in Post-operatively New Onset Myasthenia Gravis in Thymoma Patients
Cancer Research on Prevention and Treatment.2023;50(10):941-945. doi:10.3971/j.issn.1000-8578.2023.23.0469
Patients with thymoma without preoperative myasthenia gravis may develop symptoms of myasthenia gravis after tumor resection. A comprehensive understanding toward this rare clinical phenomenon is lacking. Recent studies indicate that post-operatively new onset myasthenia gravis (ponoMG) is the result of multiple mechanisms and their interactions, which may be related to the thymoma-mediated production, release and long-term presence of abnormal T cells and autoimmune antibodies in the periphery, as well as the presence of ectopic thymus and late recurrence of thymoma. Preoperative antibody titer is the main predictor. The treatment strategy is based on anticholinesterase drugs and hormonal therapy. In this study, we review the incidence, pathogenesis, predictors, and prevention and treatment strategies of ponoMG.
Mechanism of Cryptotanshinone Inhibiting Proliferation of Human Breast Cancer MCF7 Cells
Cancer Research on Prevention and Treatment.2023;50(10):946-954. doi:10.3971/j.issn.1000-8578.2023.23.0116
Objective To investigate the inhibitory effect of cryptotanshinone (CPT) on human breast cancer cell MCF7 and its mechanism. Methods The survival rate of MCF7 cells was measured by MTT assay. Cell apoptosis was detected by Annexin V/PI assay and Hoechst 33258 fluorescence staining assay. Cell cycle and reactive oxygen species were detected by flow cytometry. Cell migration and invasion were detected by cell scratch test and Transwell chamber test. The surface molecules CD44 and CD24 were detected by flow cytometry and microsphere culture. The expression of cell-associated proteins was detected by Western blot. Results CPT inhibited the proliferation of MCF7 cells in a dose-dependent manner, and the 24 h IC 50 value was 19.24 μmol/L. Compared with the untreated group, the CPT-treated group showed cell cycle arrested in the S phase, and apoptosis was induced. The results of the cell scratch and Transwell chamber tests showed that CPT significantly inhibited the migration and invasion of MCF7 cells. Furthermore, CPT reduced the CD24-/LowCD44+ cell population in MCF7 cell-derived microspheres. Western blot results showed that CPT could up-regulate the expression of Bax protein, down-regulate the expression of BCL-2, PI3K-p85, Akt, N-cadherin, Twist1, Sox2, Oct4, and Nanog protein, effectively inhibit the phosphorylation of ER-α, and decrease the expression of ABCG2. Conclusion CPT can inhibit the proliferation of MCF7 cells by inhibiting the migration and invasion of MCF7 cells, decreasing the number of CD24-/lowCD44+ cells and affecting the expression of tumor stem cell-related proteins.
Cancer Research on Prevention and Treatment.2023;50(10):955-959. doi:10.3971/j.issn.1000-8578.2023.23.0301
Objective To explore the effects and mechanism of LASP1 gene expression on the proliferation, migration, and invasion of human colorectal cancer (LOVO) cells. Methods LASP1 overexpression plasmids and LASP1 interference plasmids were constructed and transfected to LOVO cells. qRT-PCR was used to detect LASP1 mRNA expression and validate the transfection. MTT method and Tunel staining were used to detect cell proliferation and apoptosis, respectively, and scratch test and Transwell test were employed to determine the migration and invasion abilities of cells. Western blot was applied to analyze the expression of LASP1, p-FAK/FAK, and p-AKT/AKT protein in cells. Results The plasmids were successfully transfected. LASP1 overexpression increased the proliferation, migration, and invasion of LOVO cells, decreased the apoptosis, and increased LASP1, p-FAK/FAK, p-AKT/AKT protein expression (P < 0.01). LASP1 knockdown reduced the proliferation, migration, and invasion of LOVO cells, increased the apoptosis, and decreased LASP1, p-FAK/FAK, and p-AKT/AKT protein expression (P < 0.01). Conclusion LASP1 positively regulates the FAK/AKT signaling pathway to promote the proliferation, migration, and invasion of LOVO cells.
Cancer Research on Prevention and Treatment.2023;50(10):960-967. doi:10.3971/j.issn.1000-8578.2023.22.1513
Objective To evaluate predictive factors affecting the short-term efficacy of PD-1 inhibitors in non-small cell lung cancer (NSCLC) and to construct a prediction model. Methods From October 2019 to November 2021, 221 patients with advanced NSCLC who met the inclusion criteria and were treated with PD-1 inhibitors were prospectively enrolled. Patients who were enrolled before May 1st, 2021 were included inthe modeling group (n =149), whereas those who enrolled thereafter were included in the validation group (n =72). The general clinical data of patients, information of the four TCM diagnoses were collected, and TCM syndrome elements were identified. R software version 4.0.4 was used in constructing a nomogram clinical prediction model of objective response rate. The predictive ability and discrimination of the model were evaluated and externally validated by using a validation group. Results After two to four cycles of PD-1 inhibitor therapy in 221 patients, the overall objective response rate was 44.80%. Multivariate logistic regression analysis of the modeling group showed that the TPS score (OR =0.261, P =0.001), number of treatment lines (OR =3.749, P =0.002), treatment mode (OR =2.796, P =0.019), qi deficiency disease syndrome elements (OR =2.296, P =0.043), and syndrome elements of yin deficiency disease (OR =3.228, P =0.005) were the independent predictors of the short-term efficacy of PD-1 inhibitors. Based on the above five independent predictors, a nomogram prediction model for the short-term efficacy of PD-1 inhibitors was constructed. The AUC values of the modeling and validation groups were 0.8317 and 0.7535, respectively. The calibration curves of the two groups showed good agreement between the predicted and true values. The mean absolute errors were 0.053 and 0.039, indicating that the model has good predictive performance. Conclusion The nomogram model constructed on the basis of the syndrome elements of Qi-deficiency disease and Yin-deficiency syndrome of TCM, as well as TPS score, number of treatment lines and treatment mode, is a stable and effective tool for predicting the short-term efficacy of PD-1 inhibitors in advanced non-small cell lung cancer.
Clinical Prediction of Prognosis of Retinoblastoma Based on Nomogram
Cancer Research on Prevention and Treatment.2023;50(10):968-973. doi:10.3971/j.issn.1000-8578.2023.23.0232
Objective To investigate the independent risk factors affecting prognosis of patients with retinoblastoma (RB) and construct a nomogram to predict prognosis of patients with RB. Methods Data of 759 RB patients were collected from the SEER database. Patients were randomly assigned to the training group and validation group in a 7:3 ratio. Univariate and multivariate Cox proportional hazard regression analyses were used to determine the independent prognostic factors, based on which a nomogram was constructed. C index, calibration curve, and ROC curve were used to evaluate the predictive efficiency and calibration degree of the nomogram. Results Multivariate analysis identified independent risk factors associated with overall survival, namely, T stage and SEER stage. The C-index of SEER training set was 0.765 (95%CI : 0.744-0.786), the calibration curve was drawn, and the observed and predicted values overlapped well, indicating good consistency. The ROC curve showed that the nomogram could accurately predict three-year (AUC=0.743), five-year (AUC=0.734) and 10-year (AUC=0.720) survival rates of RB patients. Conclusion T stage and SEER stage are independent risk factors related to prognosis of RB patients, and the nomogram can accurately predict the three-year, five-year, and 10-year overall survival rates of patients.
Cancer Research on Prevention and Treatment.2023;50(10):974-980. doi:10.3971/j.issn.1000-8578.2023.23.0038
Objective To investigate the differential metabolites of lymph node metastasis in pancreatic ductal carcinoma (PDAC) and provide new ideas for the pathogenesis, early diagnosis and treatment of metastatic pancreatic cancer. Methods Forty serum specimens of patients with pancreatic ductal carcinoma were collected and divided into lymph node metastasis group (18 cases) and non-metastasis group (22 cases). Thirty-one serum specimens were also collected from the healthy control group. Liquid chromatographytandem mass spectrometry was used to analyze the differential metabolites and metabolic pathways between patients with PDAC and healthy controls as well as between lymph node metastasis and non-metastasis groups. Results Principal component analysis and partial least squares-discriminant analysis revealed statistically significant differences in metabolites and metabolic pathways between patients with PDAC and the healthy controls and between lymph node metastasis and non-metastasis groups. The differences in profiles were also statistically significant. Seventy-six different metabolites and 11 metabolic pathways were screened between patients with PDAC and the healthy controls, among which phenylalanine metabolism and histidine metabolism were the two most influential metabolic pathways. Four different metabolites were screened between lymph node metastasis and non-metastasis groups, and the expression of ethopropazine and phenylalanine were upregulated but the expression of tetrahydrodeoxycorticosterone and oxprenolol were downregulated. Conclusion Metabolites are significantly altered in the lymph node metastasis group of patients with PDAC compared with the non-metastasis group. Ethopropazine, phenylalanine, tetrahydrodeoxy corticosterone, and oxprenolol are potential biomarkers of lymph node metastasis in patients with PDAC.
Cancer Research on Prevention and Treatment.2023;50(10):981-987. doi:10.3971/j.issn.1000-8578.2023.23.0223
Objective To compare the diagnostic performance of PI-RADS v2.1 and PI-RADS v2 in the detection of clinically significant prostate cancer(csPCa) by Meta-analysis. Methods The major biomedical databases were searched (CNKI, CBM, Medline, and Embase) with the keywords "PIRADS v2.1" or "PI-RADS v2.1". The Quality Assessment of Diagnostic Accuracy Studies Tool v2 (QUADAS-2) was used to evaluate literature quality. Meta-analysis was performed using STATA17.0 and ReMan5.4 software. Forest plots were used to represent the sensitivity and specificity of PI-RADS v2.1 and PI-RADS v2 for each study. Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were combined, and diagnostic performance was evaluated using asummary receiver operating characteristic curve (SROC). Subgroup analysis was performed on three covariables: tumor location, threshold, and the nationality of authors. Results A total of 12 studies were included, involving 3 158 patients and 3 243 lesions. Forall zones and the whole gland, PI-RADS v2.1 had a larger area under the SROC curve (AUC) for csPCa performance, compared with PI-RADS v2. Subgroup analysis: PI-RADS v2.1 also had a larger area under the SROC (AUC) to detect transitional zone csPCa. Different diagnostic thresholds: when a score of 4 was used for the threshold, PI-RADS v2.1 had the maximum area under SROC (AUC) for csPCa performance detection. Author nationality: Researches of PI-RADS v2.1 in Chinese authors had the largest area under the SROC (AUC) in detecting csPCa performance. Conclusion Compared with PI-RADS v2, the diagnostic performance of PI-RADS v2.1 in detecting csPCa is not obviously improved and overall specificity is still low.
Country
China
Publisher
Magazine Office of Cancer Research On Prevention and Treatment
ElectronicLinks
http://www.zlfzyj.com/EN/1000-8578/home.shtmlEditor-in-chief
Shaozhong WEI
zlfzyjzz@vip.163.com
Abbreviation
CRPT
Vernacular Journal Title
肿瘤防治研究
ISSN
1000-8578
EISSN
Year Approved
2023
Current Indexing Status
Currently Indexed
Start Year
1973
Description
"Cancer Research on Prevention and Treatment" was created in 1973, as the first independent national professional academic journal about cancer research. It was in charged by Health Commission of Hubei Province, and hosted by Hubei Cancer Hospital and Chinese Anti-cancer Association. This journal is a Chinese Papers and Statistics Science and Technology Source journal, a best medical journal of Hubei Province, and China Anti-cancer Association series. It is indexed by Scopus (Netherland), DOAJ (Sweden), EBSCO (the United States), ProQuest (the United States), CA (the United States), Ulrichweb (the United States), CABI (Britain), JSTChina (Japan), IC (Poland), HINARI (Switzerland) and all major databases. The Editorial Board includes academicians of Chinese Academy of Sciences and academicians of Chinese Academy of Engineering Lu Shixin, Liu Xinyuan, Sun Yan HAO Xishan and other tumor scientists in China, more than 70 authoritative experts. And more than 200 domestic and foreign scholars with edge-cutting knowledge and broad impacts on various fields of cancer research compose expert team of reviewers, who play an unparalleled role to ensure the quality of this journal. "Cancer Research On Prevention and Treatment” mainly report national and international latest research results and new progress, facing research-oriented readers and professional medical staff in Cancer research. The main sections include: thematic forums, basic research, clinical research, clinical diagnosis, clinical, epidemiological, research briefings, technical communications, abstracts, review, short case, and communications. It is a mirror and window for the field of cancer research on prevention and treatment.
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)